Incyte announces FDA approval of Jakafi for treatment of chronic graft-versus-host disease
Incyte has announced that the FDA has approved Jakafi (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in… read more.